Plain-English translation of NCT06414096 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing pulsatile intravenous FSH (follicle-stimulating hormone), a fertility medication, to see if it can help women with obesity who have been unable to get pregnant. Researchers will compare two ways of delivering the same medication: daily injections under the skin (the standard approach) versus doses delivered every 90 minutes through an IV pump. The goal is to understand whether the pulsing IV method might help improve fertility outcomes.
Women with obesity often face fertility challenges, and researchers want to explore whether changing how the medication is delivered—rather than the dose itself—might improve the chances of successful ovulation and pregnancy. This early-stage study aims to see if this new delivery method could eventually become an option for women in this situation.
You likely qualify if…
You likely don't qualify if…
You will visit the research center for screening tests and to sign consent forms. Then you will be randomly assigned to try one medication delivery method first (either daily injections or IV pump doses every 90 minutes), and in a later cycle, you'll try the other method so researchers can compare how your body responds to each. You'll receive the same total daily hormone dose in both cycles; only the delivery method changes. The study involves wearing a portable infusion pump and regular check-in visits to monitor your progress.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
United States